Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Power of Prescription Drug Monitoring Programs (PDMP) in an American Health Crisis

A 2010 national youth drug abuse study revealed some disturbing results. In 2009, the drugs of choice for 6 of 10 drug abusers in the 12th grade were prescription pharmaceuticals. Likewise, data from a 2008 SAMSHA report revealed that the previous decade had seen a four-fold increase in the number of those seeking treatment for addiction…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

A 2010 national youth drug abuse study revealed some disturbing results. In 2009, the drugs of choice for 6 of 10 drug abusers in the 12th grade were prescription pharmaceuticals. Likewise, data from a 2008 SAMSHA report revealed that the previous decade had seen a four-fold increase in the number of those seeking treatment for addiction to prescription painkillers. In response to the serious public health problem in this country, efforts are underway to combat this growing threat. One solution is the advent of Prescription Drug Monitoring Programs (PDMP).

What is a PDMP?

PDMP is a healthcare tool with a variety of applications. The first PDMP appeared in California in 1939, primarily as a benefit for law enforcement tracking illegal drug behaviors. Today’s PDMP has evolved; as an online database of prescribing and dispensing data, PDMP helps identify when a patient obtains multiple prescriptions from different practitioners. Each database is state-run and used to address prescription drug diversion and abuse. PDMPs serve multiple functions. A PDMP is a patient care tool, a drug epidemic early warning system, and a drug diversion and insurance fraud investigation mechanism. The goal of the PDMP is to reduce the impact of prescription drug abuse and diversion.

Areas of Current and Future PDMP Impact

Not all states have PDMP requirements. Those who currently require health care personnel to utilize this system are Arizona, Connecticut, Maine, Minnesota, New York, Virginia, North Carolina, and Rhode Island. These states are seeing drastically reduced incidences of fraudulent patient behavior.

This is especially true in highly populated states such as New York, where improved visibility into prescribing patterns and potential drug-seeking behaviors has been critical to combating the practice of “doctor shopping,” as described above, in which drug addicts and system abusers go from clinic to clinic amassing a pile of prescriptions for the desired controlled substances. Looking toward the future, 12 states have requirements pending, and the hope is that the 29 states plus DC and Guam who currently have no requirement will decide to follow suit soon.

New York’s successful program has expanded to include access to other state databases and information, and this transparency and interoperability might be a prediction of the future of PDMP.

Overall Benefits

Data regarding PDMP use by state clearly shows positive benefits in the states that use these tools. While research into PDMP effectiveness is ongoing, a 2012 study looked at rates of painkiller abuse and misuse in PDMP vs. non-PDMP states from 2003 to 2009 and discovered that in non-PDMP states, rates of abuse and misuse increased more rapidly than in states with such programs.

But PDMPs are not just concerned with legality. Hand-in-hand with reduced fraudulent and abusive behavior is the improvement of identification of and treatment options for those spiraling in the tornado of the addiction epidemic, perhaps the real crowning achievement of these programs. A hallmark of addiction is a lack of self-awareness and honesty regarding one’s own harmful behaviors, and the PDMP becomes a life-saving tool in which doctors and patients can have the transparent conversations needed to kick-start recovery.

DrFirst and ChartLogic

DrFirst has been at the forefront of electronic prescribing of controlled substances (EPCS) since it sent the nation’s first electronic prescription of a controlled substance. In our partnership with DrFirst, ChartLogic is poised to make a huge impact on this current health crisis as part of a joint effort. The marriage of our software with DrFirst’s program makes sense given the proven success of our ambulatory EHR suite that includes Electronic Medical Records, Practice Management, and Billing Services. And we are proud to be part of a solution that is not only changing lives, but also saving them

Read more at chartlogic.com

Sources:

http://www.chartlogic.com/blog/the-power-of-prescription-drug-monitoring-programs/#_ednref1

https://www.ncjrs.gov/pdffiles1/ondcp/pdmp.pdf

https://searchandrescueusa.org/monitoryourpatients/?utm_source=google&utm_medium=ppc&utm_campaign=2018_PFDK_Nonbrand_PDMP&utm_term=pdmp

https://healthitanalytics.com/news/ny-expands-prescription-drug-monitoring-program-to-25-states

https://www.drugrehab.org/the-benefits-of-prescription-drug-monitoring-programs-pdmp/

https://www.drfirst.com/resources/e-prescribing-mandate-map/

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512